IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma
FPI achieved for first-in-class combination of IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor). IDE161 (PARG) induced accumulation of TOP1 lesions enhances the... Read more.
Leidos completes $2.4 billion acquisition of ENTRUST
RESTON, Va., March 30, 2026 /PRNewswire/ — Leidos (NYSE:LDOS) has completed its previously announced approximately $2.4 billion acquisition of ENTRUST Solutions... Read more.
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma
FPI achieved for first-in-class combination of IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor). IDE161 (PARG) induced accumulation of TOP1 lesions enhances the... Read more.
Search Homes and See What You Can Afford with the New Realtor.com® App in ChatGPT
The app simplifies critical budget and location decisions for home shoppers, while also safeguarding MLS data AUSTIN, Texas, March 30, 2026 /PRNewswire/ —... Read more.
Leidos completes $2.4 billion acquisition of ENTRUST
RESTON, Va., March 30, 2026 /PRNewswire/ — Leidos (NYSE:LDOS) has completed its previously announced approximately $2.4 billion acquisition of ENTRUST Solutions... Read more.
From Experience to Trust: KuCoin Connects Crypto with Culture at Tomorrowland Winter
PROVIDENCIALES, Turks and Caicos Islands, March 30, 2026 /PRNewswire/ — KuCoin, a leading global crypto platform built on trust, concluded its activation at... Read more.
Search Homes and See What You Can Afford with the New Realtor.com® App in ChatGPT
The app simplifies critical budget and location decisions for home shoppers, while also safeguarding MLS data AUSTIN, Texas, March 30, 2026 /PRNewswire/ —... Read more.
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma
FPI achieved for first-in-class combination of IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor). IDE161 (PARG) induced accumulation of TOP1 lesions enhances the... Read more.
Huawei Receives Frost & Sullivan’s 2025 Global Technology Innovation Leadership Recognition in Telecom DC Power
Huawei is recognized for redefining the functional potential of telecom energy infrastructure through cloud-based intelligent battery control, propelling innovation... Read more.
Ekinops signs a Memorandum of Understanding with a tier-1 European telecom operator for the deployment of a large scale optical network
PARIS, March 30, 2026 /PRNewswire/ — EKINOPS (ISIN: FR0011466069) (Euronext Paris: EKI), a leading provider of optical networks, connectivity and SASE cybersecurity... Read more.